AIM: To determine the incidence and characteristics of intestinal and extra-intestinal cancers among patients with inflammatory bowel disease in a Spanish hospital and to compare them with those of the local population. METHODS: This was a prospective, observational, 7-year follow-up, cohort study. Cumulative incidence, incidence rates based on person-years of follow-up and relative risk were calculated for patients with inflammatory bowel disease and compared with the background population. The incidence of cancer was determined using a hospital-based data registry from Hospital Universitario de Fuenlabrada. Demographic data and details about time from diagnosis of inflammatory bowel disease to occurrence of cancer, disease extent, inflammatory bowel disease treatment, cancer therapy and cancer evolution were also collected in the inflammatory bowel disease cohort. RESULTS: Eighteen of 590 patients with inflammatory bowel disease developed cancer [cumulative incidence = 3% (95%CI: 1.58-4.52) vs 2% (95%CI: 1.99-2.11) in the background population; RR = 1.5; 95%CI: 0.97-2.29]. The cancer incidence among inflammatory bowel disease patients was 0.53% (95%CI: 0.32-0.84) per patient-year of follow-up. Patients with inflammatory bowel disease had a significantly increased relative risk of urothelial carcinoma (RR = 5.23, 95%CI: 1.95-13.87), appendiceal mucinous cystadenoma (RR = 36.6, 95%CI: 7.92-138.4), neuroendocrine carcinoma (RR = 13.1, 95%CI: 1.82-29.7) and rectal carcinoid (RR = 8.94, 95%CI: 1.18-59.7). Colorectal cancer cases were not found. CONCLUSION: The overall risk of cancer did not significantly increase in our inflammatory bowel disease patients. However, there was an increased risk of urinary bladder cancer and, with less statistical power, an increased risk of appendiceal mucinous cystadenoma and of neuroendocrine tumors. Colorectal cancer risk was low in our series.
AIM: To determine the incidence and characteristics of intestinal and extra-intestinal cancers among patients with inflammatory bowel disease in a Spanish hospital and to compare them with those of the local population. METHODS: This was a prospective, observational, 7-year follow-up, cohort study. Cumulative incidence, incidence rates based on person-years of follow-up and relative risk were calculated for patients with inflammatory bowel disease and compared with the background population. The incidence of cancer was determined using a hospital-based data registry from Hospital Universitario de Fuenlabrada. Demographic data and details about time from diagnosis of inflammatory bowel disease to occurrence of cancer, disease extent, inflammatory bowel disease treatment, cancer therapy and cancer evolution were also collected in the inflammatory bowel disease cohort. RESULTS: Eighteen of 590 patients with inflammatory bowel disease developed cancer [cumulative incidence = 3% (95%CI: 1.58-4.52) vs 2% (95%CI: 1.99-2.11) in the background population; RR = 1.5; 95%CI: 0.97-2.29]. The cancer incidence among inflammatory bowel diseasepatients was 0.53% (95%CI: 0.32-0.84) per patient-year of follow-up. Patients with inflammatory bowel disease had a significantly increased relative risk of urothelial carcinoma (RR = 5.23, 95%CI: 1.95-13.87), appendiceal mucinous cystadenoma (RR = 36.6, 95%CI: 7.92-138.4), neuroendocrine carcinoma (RR = 13.1, 95%CI: 1.82-29.7) and rectal carcinoid (RR = 8.94, 95%CI: 1.18-59.7). Colorectal cancer cases were not found. CONCLUSION: The overall risk of cancer did not significantly increase in our inflammatory bowel diseasepatients. However, there was an increased risk of urinary bladder cancer and, with less statistical power, an increased risk of appendiceal mucinous cystadenoma and of neuroendocrine tumors. Colorectal cancer risk was low in our series.
Authors: R Caprilli; M A Gassull; J C Escher; G Moser; P Munkholm; A Forbes; D W Hommes; H Lochs; E Angelucci; A Cocco; B Vucelic; H Hildebrand; S Kolacek; L Riis; M Lukas; R de Franchis; M Hamilton; G Jantschek; P Michetti; C O'Morain; M M Anwar; J L Freitas; I A Mouzas; F Baert; R Mitchell; C J Hawkey Journal: Gut Date: 2006-03 Impact factor: 23.059
Authors: Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes Journal: Gastroenterology Date: 2004-02 Impact factor: 22.682
Authors: Martine M Ros; H Bas Bueno-de-Mesquita; Ellen Kampman; Frederike L Büchner; Katja K H Aben; Lars Egevad; Kim Overvad; Anne Tjønneland; Nina Roswall; Francoise Clavel-Chapelon; Marie Christine Boutron-Ruault; Sophie Morois; Rudolf Kaaks; Birgit Teucher; Steffen Weikert; Anne von Ruesten; Antonia Trichopoulou; Androniki Naska; Vassiliki Benetou; Calogero Saieva; Valeria Pala; Fulvio Ricceri; Rosario Tumino; Amalia Mattiello; Petra H M Peeters; Carla H van Gils; Inger T Gram; Dagrun Engeset; Maria-Dolores Chirlaque; Eva Ardanazx; Laudina Rodríguez; Pilar Amanio; Carlos A Gonzalez; María José Sánchez; David Ulmert; Roy Ernström; Börje Ljungberg; Naomi E Allen; Timothy J Key; Kee-Tee Khaw; Nick Wareham; Nadia Slimani; Isabelle Romieu; Lambertus A Kiemeney; Elio Riboli Journal: Eur J Cancer Date: 2012-08-03 Impact factor: 9.162
Authors: Giovanni Vitale; Alessandra Dicitore; Luigi Barrea; Emilia Sbardella; Paola Razzore; Severo Campione; Antongiulio Faggiano; Annamaria Colao; Manuela Albertelli; Barbara Altieri; Filomena Bottiglieri; Federica De Cicco; Sergio Di Molfetta; Giuseppe Fanciulli; Tiziana Feola; Diego Ferone; Francesco Ferraù; Marco Gallo; Elisa Giannetta; Federica Grillo; Erika Grossrubatscher; Elia Guadagno; Valentina Guarnotta; Andrea M Isidori; Andrea Lania; Andrea Lenzi; Fabio Lo Calzo; Pasquale Malandrino; Erika Messina; Roberta Modica; Giovanna Muscogiuri; Luca Pes; Genoveffa Pizza; Riccardo Pofi; Giulia Puliani; Carmen Rainone; Laura Rizza; Manila Rubino; Rosa Maria Ruggieri; Franz Sesti; Mary Anna Venneri; Maria Chiara Zatelli Journal: Rev Endocr Metab Disord Date: 2020-09-15 Impact factor: 9.306